The Prognostic Value of Del(1p32)in Patients with Newly Diagnosed Multiple Myeloma
10.19746/j.cnki.issn1009-2137.2024.03.017
- VernacularTitle:1p32缺失在初诊多发性骨髓瘤患者中的预后意义
- Author:
Rui GUO
1
;
Xu-Xing SHEN
;
Yuan XIA
;
Yuan-Yuan JIN
;
Jian-Yong LI
;
Li-Juan CHEN
;
Hai-Rong QIU
Author Information
1. 南京医科大学第一附属医院(江苏省人民医院)血液科,江苏南京 210029
- Keywords:
multiple myeloma;
del(1p32);
prognosis
- From:
Journal of Experimental Hematology
2024;32(3):768-773
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the prognostic value of del(1p32)in patients with newly diagnosed multiple myeloma(MM).Methods:The clinical data of 341 newly diagnosed MM attended in Jiangsu Province Hospital were retrospective analyzed.Clinical characteristic combined with genetic features,especially del(1p32),were analyzed for survival and prognostic of patients.Results:Among the 341 patients with newly diagnosed MM,24(7.0％)patients were del(1p32)positive.The progression-free survival(PFS)and overall survival(OS)were significantly shorter in MM patients with del(1p3 2)than those without de1(1p32)(PFS:P＜0.001;OS:P＜0.001).The COX proportional-hazards model showed that del(1 p32)was an independent risk factor for PFS and OS of patients with MM.The patients with both 1q21 gain/amplification and del(1p32),as"double-hit chromosome 1",have worse prognosis than those with only 1q21 gain/amplification or only del(1 p32)(PFS:P＜0.001;OS:P＜0.001).Conclusion:Del(1p32)is an independent risk factor for PFS and OS of patients with MM.Del(1p32)detection should be widely used in the prognostic analysis for newly diagnosed MM patients.
